Microbiota Restoration in Recurrent C. difficile and COVID-19
| Overview / Abstract: |
In this activity, Dr. Paul Feuerstadt and Dr. Sahil Khanna discuss how the global COVID-19 pandemic presents increasing safety measures for patients with recurrent Clostridioides difficile Infection (rCDI) that are candidates for fecal microbiota transplantation (FMT). In this video-based format, our faculty share why clinicians need to be aware of screening and safety protocols, and how to manage rCDI patients during this unprecedented time. While the incidence of multiply recurrent C. difficile continues to rise, FMT has emerged as a means to break the cycle. Amid the current COVID-19 pandemic, clinicians should be aware of the additional safety concerns that have arisen. Expert faculty will discuss approaches to FMT including sourcing and screening of donor stool, which requires heightened safety measures during the COVID-19 pandemic. |
|
Expiration |
Sep 06, 2020 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
.75 AMA PRA Category 1 Credit(s) |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Paul Feuerstadt MD, FACG, AGAF Sahil Khanna, MBBS, MS |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc. |
|
Keywords / Search Terms |
ACHL CME, CE, CME/CE, Continuing Medical Education, Online Learning, Webcast, C. difficile, CDI, Dr. Feuerstadt, Dr. Khanna, Paul Feuerstadt, Sahil Khanna, COVID-19, COVID, coronavirus, virus, pandemic, transmission, recurrent, recurrence, infection, infectious disease, gastrointestinal, gastroenterology, physician, fecal microbiota transplantation, FMT, stool, donor, IDSA/SHEA, FDA, efficacy, safety, screening, immunocompromised Free CE CME |
|